We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editor's Correspondence |

Dalteparin vs Warfarin in Hip Arthroplasty Patients

Albert E. Bajjoka, PHARMD, BCPS
Arch Intern Med. 2001;161(5):771-778. doi:.
Text Size: A A A
Published online


I read with interest the article by Hull et al1 comparing long-term dalteparin therapy with short-term in-hospital warfarin therapy in patients undergoing hip arthroplasty. I would like to make the following comments regarding this study.

Because the study compared long-term dalteparin therapy (average of 35 days) with short-term warfarin therapy (average of 6 days), the conclusions of the study do not necessarily mean that dalteparin is superior to warfarin in patients with hip arthroplasty. Had these agents been administered for the same period (average of 35 days), better and more balanced conclusions could have been made about their comparative efficacy. I concur with the authors' valid observation about the currently shorter in-hospital stay for most hip arthroplasty patients. The average in-hospital stay at my institution ranges from 3 to 4 days, depending on the individual orthopedic surgeon. Because the currently short in-hospital stay for hip arthroplasty patients was quoted as a potential hindrance towards an adequate anticoagulation period in these patients, why wasn't warfarin therapy extended as long as the dalteparin arm of the study?

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

Users' Guides to the Medical Literature
Assessing the Strength of Recommendations: The GRADE Approach

Users' Guides to the Medical Literature
Are the Results Valid?